5-(4-甲基哌嗪)-2-硝基苯胺 | 23491-48-7

• 物质功能分类: 医药中间体 - 杂环化合物 - 哌嗪类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 5-(4-甲基哌嗪)-2-硝基苯胺
• 英文名称: 5-(4-methylpiperazine-1-yl)-2-nitroaniline
• 英文别名: 5-(4-methylpiperazin-1-yl)-2-nitroaniline
• CAS: 23491-48-7
• 化学式: C₁₁H₁₆N₄O₂
• mdl: MFCD00545964
• 分子量: 236.274
• InChiKey: MWLBMGPQZJDFKZ-UHFFFAOYSA-N

物化性质

• 熔点：
  152-155°C
• 沸点：
  444.2±45.0 °C(Predicted)
• 密度：
  1.264±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  78.3
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933599090
• 危险品标志：
  Xi
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-(4-Methylpiperazin-1-yl)-2-nitrophenylamine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-(4-Methylpiperazin-1-yl)-2-nitrophenylamine
CAS number: 23491-48-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H16N4O2
Molecular weight: 236.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-(4-甲基哌嗪)-2-硝基苯胺 在 palladium on activated charcoal potassium tert-butylate 、 氢气 作用下， 以 四氢呋喃 、 乙醇 、 甲苯 为溶剂， 反应 10.0h， 生成 多韦替尼
  参考文献：
  名称：

  The Chemical Development of CHIR-258

  摘要：

  这篇论文是关于CHIR-258（4-氨基-5-氟-3-[6(4-甲基-1-哌嗪基)-1H-苯并咪唑-2-基]-2(1H)-喹啉酮，DL-乳酸盐）的早期化学开发案例。CHIR-258是一种血管内皮生长因子（VEGF）激酶抑制剂，用于治疗实体和血液系统癌症。文章涵盖了化学开发工作的各个方面。特别讨论了药物化学路线的评估、放大生产、盐制备、工艺杂质、过程控制方法的开发、供应途径的开发、技术转移给合同制造组织（CMO）以及中试生产。还讨论了化学开发的监管要求的一些有趣点。

  DOI：

  10.2533/chimia.2006.584
• 作为产物：
  描述：

  N-甲基哌嗪 、 5-氟-2-硝基苯胺 在 N,N-二异丙基乙胺 作用下， 以 N-甲基吡咯烷酮 为溶剂， 反应 4.0h， 以83%的产率得到5-(4-甲基哌嗪)-2-硝基苯胺
  参考文献：
  名称：

  3-（5'-取代）-苯并咪唑-5-（1-（3,5-二氯吡啶-4-基）乙氧基）-1 H-吲唑类化合物作为有效的成纤维细胞生长因子受体抑制剂的发现：设计，合成和生物学评估

  摘要：

  鉴于成纤维细胞生长因子受体（FGFR）在促进癌症形成和进展以及引起对批准疗法的抗性中起关键作用，因此它是癌症治疗的有吸引力的肿瘤学靶标。在本文中，我们描述了有效的泛FGFR抑制剂（的识别- [R ）- 21C（FGFR1-4 IC 50个的值0.9，2.0，2.0，和6.1 nM的，分别地）。化合物（R）-21c对一组FGFR扩增的细胞系表现出优异的体外抑制活性。Western印迹分析表明（[R ）- 21C抑制FGF / FGFR和下游信号传导途径在纳摩尔浓度。而且， （[R ）- 21C提供在NCI-H1581肿瘤生长（96.9％TGI）几乎完全抑制（FGFR1扩增）在通过口服给药，剂量为10毫克/公斤/ QD异种移植小鼠模型。

  DOI：

  10.1021/acs.jmedchem.6b00056

文献信息

• [EN] PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS<br/>[FR] PYRROLOTRIAZINES EN TANT QU'INHIBITEURS D'ALK ET DE JAK2
  申请人：CEPHALON INC

  公开号：WO2010071885A1

  公开（公告）日：2010-06-24

  The present invention provides a compound of formula (I) or a salt form thereof, wherein Q1, Q2, Q3, and Q4 are as defined herein. The compound of formula (I) has ALK and/or JAK2 inhibitory activity, and may be used to treat proliferative disorders.

  本发明提供了一种式（I）的化合物或其盐形式，其中Q1、Q2、Q3和Q4如本文所定义。式（I）的化合物具有ALK和/或JAK2抑制活性，并可用于治疗增殖性疾病。
• New dimeric carbazole–benzimidazole mixed ligands for the stabilization of human telomeric G-quadruplex DNA and as telomerase inhibitors. A remarkable influence of the spacer
  作者：Basudeb Maji、Krishan Kumar、K. Muniyappa、Santanu Bhattacharya

  DOI：10.1039/c5ob00675a

  日期：——

  G-quadruplex DNA binding dimeric ligands and their telomerase inhibition activity are reported.

  G-四链体DNA结合二聚配体及其端粒酶抑制活性已被报道。
• Substituted benzazoles and methods of their use as inhibitors of Raf kinase
  申请人：——

  公开号：US20040122237A1

  公开（公告）日：2004-06-24

  New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.

  提供了新的替代苯唑化合物、组合物和抑制人类或动物主体中Raf激酶活性的方法。这些新化合物组合物可以单独使用，也可以与至少一种额外药物结合，用于治疗由Raf激酶介导的疾病，如癌症。
• 2-[1H-Benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors
  申请人：Aurrecoechea Natalia

  公开号：US20100081653A1

  公开（公告）日：2010-04-01

  2-[1H-benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and their salts are kinase inhibitors, useful in the treatment of cancer.

  2-[1H-苯并咪唑-2(3H)-基]-2-(嘧啶-2-基)乙酰胺和2-[苯并噻唑-2(3H)-基]-2-(嘧啶-2-基)乙酰胺及其盐是激酶抑制剂，在癌症治疗中有用。
• 一种苯并咪唑类化合物及其制备方法和在制备铁死亡抑制剂中的应用
  申请人：中山大学

  公开号：CN112939943B

  公开（公告）日：2022-09-16

  本发明公开了一种苯并咪唑类化合物及其制备方法和在制备铁死亡抑制剂中的应用。该苯并咪唑类化合物具有如式(Ⅰ)或式(Ⅱ)所示结构：本发明提供的苯并咪唑类化合物通过在R1位置引入亲脂性基团，及在R2位置引入特定的基团，得到的化合物具有较好的铁死亡抑制活性，可作为防治神经系统疾病如中风的一种先导化合物。